Jeremiah Rastegar
Research Subjects
Jeremiah Rastegar has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey J. Ellis
US VEO, GSK, Collegeville, USA
2 shared publications - Suzanne W. Dixon
Humana Healthcare Research, Inc., Louisville, KY
2 shared publications Amy Hu
Humana Pharmacy Solutions, Humana Inc., Louisville, KY
1 shared publication- Andrea DeVries
Humana Healthcare Research, Inc., Louisville, Kentucky, USA
1 shared publication - Ariann Nassel
Lister Hill Center for Health Policy, University of Alabama at Birmingham, Birmingham, Alabama
1 shared publication - Dustin Marsh Long
Department of Biostatistics and Data Science, Wake Forest University, Winston-Salem, NC 27109, USA
1 shared publication
Latest Publications
- 5 November 2026
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
Feasibility of applying generative AI to create managed care pharmacy formulary reviews
Purpose: Formulary reviews are used with other data sources and clinical judgement to support formulary strategies, such as placement for existing and new-to-market drugs. We describe the pharmacy resident user experience and assessed the feasibility of using clinical and research-focused generative artificial (genAI) tools in a managed care setting for creating formulary reviews for 2 complex and rare diseases: multiple sclerosis and age-related macular degeneration. This allowed genAI feasibility assessment for disease states with less well-defined guidelines and fewer data sources from which to draw information. Summary: Users reported a steeper learning curve with research-specific genAI systems compared with pharmacy-focused tools. Users noted pharmacy-focused genAI tools may produce more current drug pipeline information, relative to research-focused AI systems. Prompt engineering, the skill of creating effective prompts to elicit accurate information from genAI models, also contributed to the quality of the evidence produced, regardless of the tool used. The pharmacists noted time savings when utilizing AI compared with a completely manual data generation process involving individual searches of PubMed, business reports, FDA websites, and pharmaceutical company-related information sources. Conclusion: Pharmacists need adequate time and training to optimize prompt techniques to produce quality health- and medication-related information and must be educated on potential downsides of genAI such as inaccurate or incomplete results. With currently available tools, all generated output required careful human fact checking. With continued use and accumulating experience, the pharmacist may become more efficient over time with genAI support for formulary reviews
- 5 November 2026
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
Feasibility of applying generative AI to create managed care pharmacy formulary reviews
Purpose: Formulary reviews are used with other data sources and clinical judgement to support formulary strategies, such as placement for existing and new-to-market drugs. We describe the pharmacy resident user experience and assessed the feasibility of using clinical and research-focused generative artificial (genAI) tools in a managed care setting for creating formulary reviews for 2 complex and rare diseases: multiple sclerosis and age-related macular degeneration. This allowed genAI feasibility assessment for disease states with less well-defined guidelines and fewer data sources from which to draw information. Summary: Users reported a steeper learning curve with research-specific genAI systems compared with pharmacy-focused tools. Users noted pharmacy-focused genAI tools may produce more current drug pipeline information, relative to research-focused AI systems. Prompt engineering, the skill of creating effective prompts to elicit accurate information from genAI models, also contributed to the quality of the evidence produced, regardless of the tool used. The pharmacists noted time savings when utilizing AI compared with a completely manual data generation process involving individual searches of PubMed, business reports, FDA websites, and pharmaceutical company-related information sources. Conclusion: Pharmacists need adequate time and training to optimize prompt techniques to produce quality health- and medication-related information and must be educated on potential downsides of genAI such as inaccurate or incomplete results. With currently available tools, all generated output required careful human fact checking. With continued use and accumulating experience, the pharmacist may become more efficient over time with genAI support for formulary reviews
- Open Access
- 3 July 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (7)
Differences in the use of Medicare Advantage transportation benefits by primary care payment model and beneficiary needs
- 3 July 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (7)
Open AccessDifferences in the use of Medicare Advantage transportation benefits by primary care payment model and beneficiary needs
- Open Access
- 1 December 2023
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 29 (12) , 1267-1274
HIV preexposure prophylaxis treatment patterns in a national health plan population
Medication nonadherence diminishes the benefits of preexposure prophylaxis (PrEP) for the 1.2 million Americans at risk for HIV exposure. To describe HIV PrEP treatment patterns among Medicare Advantage Prescription Drug (MAPD) plan and commercially insured beneficiaries. This retrospective cohort study identified patients aged 16 to 89 years with at least 1 dispensing of emtricitabine-tenofovir disoproxil fumarate from July 2012, through December 2020, or emtricitabine-tenofovir alafenamide from October 2019 through December 2020, and who were continuously enrolled at least 12 months prior to and following the earliest PrEP claim. Outcomes were HIV PrEP adherence measured by proportion of days covered (PDC) using 2 binary thresholds of 0.60 (4 doses/week) and 0.80 (5-6 doses/week) and duration of index treatment episode, total time on treatment, and total number of prescription fills. The study cohort of 707 (292 MAPD plan, 415 commercial) was predominantly made up of male patients (90.0%) and resided in the South (78.9%) with a mean age of 46.2 years (MAPD plan: 54.5, commercial: 40.4). Both populations engaged in high-risk sexual behavior (All: 18.7%, MAPD plan: 16.8%, commercial: 20.0%) and experienced sexually transmitted infections (All: 3.3%, MAPD plan: 2.1%, commercial: 4.1%). The mean index treatment episode length was 297.0 days (MAPD plan: 283.6, commercial: 306.5). Total time on treatment was 477.3 days (MAPD plan: 450.7, commercial 496.0). At 3 months, 84.9% (MAPD plan: 83.6%, commercial: 85.8%) and at 12 months, 58.7% (MAPD plan: 57.2, commercial: 59.8) of patients achieved a PDC of at least 0.80. At 3 months, 100.0% (MAPD plan: 100.0%, commercial: 100.0%), and at 12 months, 74.3% (MAPD plan: 70.2%, commercial: 76.9%) of patients achieved a PDC of at least 0.60. The cohort had a mean of 16.4 fills of 30 days (MAPD plan: 16.4, commercial: 16.3) supply. There is an opportunity for clinical programs to focus on improving longer-term PrEP adherence among individuals at risk for HIV exposure.
- 1 December 2023
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 29 (12) , 1267-1274
Open AccessHIV preexposure prophylaxis treatment patterns in a national health plan population
Medication nonadherence diminishes the benefits of preexposure prophylaxis (PrEP) for the 1.2 million Americans at risk for HIV exposure. To describe HIV PrEP treatment patterns among Medicare Advantage Prescription Drug (MAPD) plan and commercially insured beneficiaries. This retrospective cohort study identified patients aged 16 to 89 years with at least 1 dispensing of emtricitabine-tenofovir disoproxil fumarate from July 2012, through December 2020, or emtricitabine-tenofovir alafenamide from October 2019 through December 2020, and who were continuously enrolled at least 12 months prior to and following the earliest PrEP claim. Outcomes were HIV PrEP adherence measured by proportion of days covered (PDC) using 2 binary thresholds of 0.60 (4 doses/week) and 0.80 (5-6 doses/week) and duration of index treatment episode, total time on treatment, and total number of prescription fills. The study cohort of 707 (292 MAPD plan, 415 commercial) was predominantly made up of male patients (90.0%) and resided in the South (78.9%) with a mean age of 46.2 years (MAPD plan: 54.5, commercial: 40.4). Both populations engaged in high-risk sexual behavior (All: 18.7%, MAPD plan: 16.8%, commercial: 20.0%) and experienced sexually transmitted infections (All: 3.3%, MAPD plan: 2.1%, commercial: 4.1%). The mean index treatment episode length was 297.0 days (MAPD plan: 283.6, commercial: 306.5). Total time on treatment was 477.3 days (MAPD plan: 450.7, commercial 496.0). At 3 months, 84.9% (MAPD plan: 83.6%, commercial: 85.8%) and at 12 months, 58.7% (MAPD plan: 57.2, commercial: 59.8) of patients achieved a PDC of at least 0.80. At 3 months, 100.0% (MAPD plan: 100.0%, commercial: 100.0%), and at 12 months, 74.3% (MAPD plan: 70.2%, commercial: 76.9%) of patients achieved a PDC of at least 0.60. The cohort had a mean of 16.4 fills of 30 days (MAPD plan: 16.4, commercial: 16.3) supply. There is an opportunity for clinical programs to focus on improving longer-term PrEP adherence among individuals at risk for HIV exposure.
- 1 July 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (5) , 1566-1573.e1
Home versus outpatient hospital intravenous immunoglobulin infusion and health care resource utilization
- 1 July 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (5) , 1566-1573.e1
Home versus outpatient hospital intravenous immunoglobulin infusion and health care resource utilization
- Open Access
- 1 March 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (3) , ofad107
Geospatial Analysis of Time to Human Immunodeficiency Virus (HIV) Diagnosis and Adult HIV Testing Coverage Highlights Areas for Intervention in the US Southeast
Background: In the United States (US), 44% of people with human immunodeficiency virus (PWH) live in the Southeastern census region; many PWH remain undiagnosed. Novel strategies to inform testing outreach in rural states with dispersed HIV epidemics are needed.Methods: Alabama state public health HIV testing surveillance data from 2013 to 2017 were used to estimate time from infection to HIV diagnosis using CD4 T-cell depletion modeling, mapped to county. Diagnostic HIV tests performed during 2013–2021 by commercial testing entities were used to estimate HIV tests per 100 000 adults (aged 15–65 years), mapped to client ZIP Code Tabulation Area (ZCTA). We then defined testing “cold spots”: those with 400 cases per 100 000 population or (2) within a county with average time to diagnosis greater than the state average to inform testing outreach.Results: Time to HIV diagnosis was a median of 3.7 (interquartile range [IQR], 0–9.2) years across Alabama, with a range of 0.06–12.25 years. Approximately 63% of counties (n = 42) had a longer time to diagnosis compared to national US estimates. Six hundred forty-three ZCTAs tested 17.3% (IQR, 10.3%–25.0%) of the adult population from 2013 to 2017. To prioritize areas for testing outreach, we generated maps to describe 47 areas of HIV-testing cold spots at the ZCTA level.Conclusions: Combining public health surveillance with commercial testing data provides a more nuanced understanding of HIV testing gaps in a state with a rural HIV epidemic and identifies areas to prioritize for testing outreach.
- 1 March 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (3) , ofad107
Open AccessGeospatial Analysis of Time to Human Immunodeficiency Virus (HIV) Diagnosis and Adult HIV Testing Coverage Highlights Areas for Intervention in the US Southeast
Background: In the United States (US), 44% of people with human immunodeficiency virus (PWH) live in the Southeastern census region; many PWH remain undiagnosed. Novel strategies to inform testing outreach in rural states with dispersed HIV epidemics are needed.Methods: Alabama state public health HIV testing surveillance data from 2013 to 2017 were used to estimate time from infection to HIV diagnosis using CD4 T-cell depletion modeling, mapped to county. Diagnostic HIV tests performed during 2013–2021 by commercial testing entities were used to estimate HIV tests per 100 000 adults (aged 15–65 years), mapped to client ZIP Code Tabulation Area (ZCTA). We then defined testing “cold spots”: those with 400 cases per 100 000 population or (2) within a county with average time to diagnosis greater than the state average to inform testing outreach.Results: Time to HIV diagnosis was a median of 3.7 (interquartile range [IQR], 0–9.2) years across Alabama, with a range of 0.06–12.25 years. Approximately 63% of counties (n = 42) had a longer time to diagnosis compared to national US estimates. Six hundred forty-three ZCTAs tested 17.3% (IQR, 10.3%–25.0%) of the adult population from 2013 to 2017. To prioritize areas for testing outreach, we generated maps to describe 47 areas of HIV-testing cold spots at the ZCTA level.Conclusions: Combining public health surveillance with commercial testing data provides a more nuanced understanding of HIV testing gaps in a state with a rural HIV epidemic and identifies areas to prioritize for testing outreach.